The vaccine against SARS-CoV-2 developed by Pfizer Inc. and BioNTech SE could become available for high-risk populations toward the end of this year if the companies are able to secure an emergency use authorization from the US Food and Drug Administration.
The US-based drug maker and German biotech submitted a request to the FDA on 20 November seeking an EUA for BNT162b2, their messenger RNA-based vaccine against SARS-CoV-2
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?